In her lawsuit, the woman is claiming that those problems were caused by blood clotting caused by her use of a NuvaRing IUD over seven years.
In her court filing, the woman said she has been forced to undergo a daily Coumadin regimen for her health problems, and suffers from depression and social anxiety.
Named as defendants are Organon Pharmaceuticals USA Inc., Organon International Inc. and Schering-Plough Corp., who, according to the court file, allegedly falsely marketed and sold the NuvaRing as a safe, efficient alternative to birth control pills.
As with the NuvaRing lawsuits in the multidistrict litigation, the Philadelphia woman claims that the defendants were negligent in not fully informing the public and health care professionals about increased risk of blood-clotting from the use of the contraceptive, according to the court filing.
The allegations cited in the multidistrict litigation claim that the NuvaRing, described by company officials as the first hormonal IUD, puts women at risk of suffering blood clots that can lead to life-threatening health problems because of the hormone mixture that prevents pregnancies.
The NuvaRing was approved by the Food and Drug Administration in 2001 after being created by Organon as a flexible IUD, or ring, hence the name. The IUD releases a low dose of etonogestrel and estrogen over three weeks, providing women the flexibility of a monthly contraceptive.
This flexibility was one of the marketing factors that made the NuvaRing what was described as an easy and healthy contraceptive choice to women who were not satisfied with the side effects caused by birth control pills and the necessity of taking them each day.
However, by 2011 the FDA released the findings of government research that put women who used the NuvaRing or other IUDs with a similar mixture of hormones at a 56 percent higher risk of suffering blood clotting that led to deep vein thrombosis a
Copyright©2012 Vocus, Inc.
All rights reserved